Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca VP Detlev Biniszkiewicz On Building An Oncology Strategy In China And Asia (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Fresh off a global deal to in-license a novel oncology molecule discovered in China, the head of strategy for AZ’s Oncology Innovative Medicine Unit speaks with PharmAsia News during the JP Morgan Healthcare Conference about how AstraZeneca’s strategy in Asia differs from its peers.

You may also be interested in...

AstraZeneca Takes Impairment Charge After Olaparib, TC-5214 Setbacks

Olaparib and TC-5214 development setbacks at AstraZeneca lead to $380 million charge in the fourth quarter, with core EPS likely at the bottom of the expected range.

AstraZeneca Invests $200 Million For Manufacturing Plant In China Medical City

AstraZeneca PLC has announced a plan to invest $200 million to build a new manufacturing plant inside Taizhou, Jiangsu-based China Medical City

Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets

WASHINGTON - AstraZeneca PLC is looking to leverage its experience in Asia to catch up with competitors in other fast growing emerging markets like Russia and Brazil, according to Steve Yang, the company's head of R&D in Asia and emerging markets. Yang, who joined AZ in January, is based in Shanghai and reports to R&D President Martin Mackay

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts